English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
A ‘Miracle’: Spinraza Gives Boy, Now 5, a Chance to Grow Up
It’s now been more than four years since Spinraza (nusinersen) was first approved by the U.S. Food and Drug Administration, and presymptomatic children with spinal muscular atrophy (SMA) who received the therapy as part of the Phase 2 NURTURE trial are growing up fast and, by all accounts, showing good progress.
Jase Yoder, 5, is one of those children. He was featured as part of “The Gene” documentary on PBS last year. In the segment, Jase, who has SMA type 1, can be seen jumping on a trampoline. Sitting up, walking, and jumping were all milestones Jase would have likely not achieved if it weren’t for Spinraza infusions. In fact, children with SMA type 1 typically don’t make it past the age of 2.
BookmarkRelated Content
-
Despite Taking Spinraza, SMA Type 1 Children Show Nonmotor ProblemsDespite its well-reported benefits in mo...
-
Safety and Efficacy Data Published for Novel Nusinersen Drug Delivery Method for Spinal Muscular Atrophy PatientsA recently published paper details the s...
-
Biogen to Launch Study of Higher Spinraza Dose in Patients With Later Onset SMABiogen announced it intends to initiate ...
-
Biogen Announces New Updates Across Its SMA Research Program at 2022 MDA ConferenceBiogen Inc. announced new data and updat...
-
Spinal Muscular Atrophy 2020: SMA Medications for Treatment Updateshttps://www.youtube.com/watch?v=dnSXnvrO...
-
SMA and Nusinersen (Spinraza) the Story so farhttps://slideplayer.com/slide/14664651/...
-
Comparison of Nusinersen and Evrysdi in the Treatment of Spinal Muscular AtrophySpinal Muscular Atrophy (SMA) is a genet...
Powered by
In partnership with
